BlackRock’s $11 billion iShares Biotechnology ETF (IBB) has surged more than 740% since its inception.
Here are its latest top 10 holdings:
1. 🇺🇸 Amgen ($AMGN.US ): 8.48%
2. 🇺🇸 Vertex Pharmaceuticals ($VRTX.US ): 7.95%
3. 🇺🇸 Gilead Sciences ($GILD.US ): 7.03%
4. 🇺🇸 Regeneron Pharmaceuticals (REGN): 5.88%
5. 🇳🇱 Argenx SE (ARGX): 3.80%
6. 🇺🇸 Moderna (MRNA): 3.42%
7. 🇺🇸 Natera (NTRA): 3.13%
8. 🇺🇸 Revolution Medicines (RVMD): 2.84%
9. 🇺🇸 Illumina (ILMN): 2.27%
10. 🇺🇸 Biogen (BIIB): 2.21%
Source: iShares data as of August 20, 2026
The iShares Biotechnology ETF (IBB) is one of the largest and most well-established exchange-traded funds focused on the U.S. biotechnology sector.
The ETF seeks to track an index that includes U.S.-listed equities in the biotechnology sector.
IBB currently has 247 holdings and about $10.6 billion in net assets. The top 10 holdings account for 47.01% of the fund’s net assets.
Unlike equal-weighted biotech funds (such as XBI), IBB tilts heavily toward profitable, revenue-generating large-cap companies. This generally makes IBB less volatile than small-cap-heavy alternatives.
Here are its latest top 10 holdings:
1. 🇺🇸 Amgen ($AMGN.US ): 8.48%
2. 🇺🇸 Vertex Pharmaceuticals ($VRTX.US ): 7.95%
3. 🇺🇸 Gilead Sciences ($GILD.US ): 7.03%
4. 🇺🇸 Regeneron Pharmaceuticals (REGN): 5.88%
5. 🇳🇱 Argenx SE (ARGX): 3.80%
6. 🇺🇸 Moderna (MRNA): 3.42%
7. 🇺🇸 Natera (NTRA): 3.13%
8. 🇺🇸 Revolution Medicines (RVMD): 2.84%
9. 🇺🇸 Illumina (ILMN): 2.27%
10. 🇺🇸 Biogen (BIIB): 2.21%
Source: iShares data as of August 20, 2026
The iShares Biotechnology ETF (IBB) is one of the largest and most well-established exchange-traded funds focused on the U.S. biotechnology sector.
The ETF seeks to track an index that includes U.S.-listed equities in the biotechnology sector.
IBB currently has 247 holdings and about $10.6 billion in net assets. The top 10 holdings account for 47.01% of the fund’s net assets.
Unlike equal-weighted biotech funds (such as XBI), IBB tilts heavily toward profitable, revenue-generating large-cap companies. This generally makes IBB less volatile than small-cap-heavy alternatives.